28468980|t|Identification of protective B-cell epitopes within the novel malaria vaccine candidate P. falciparum Schizont Egress Antigen-1
28468980|a|Naturally -acquired antibodies to PfSEA-1A are associated with protection against severe malaria in children. Vaccination of mice with PbSEA-1A decreases parasitemia and prolongs survival following Plasmodium berghei ANKA challenge. To enhance the immunogenicity of PfSEA-1A, we identified five linear, B-cell epitopes using peptide microarrays probed with anti-sera from rPfSEA-1A - vaccinated non-human primates. We evaluated the relationship between epitope -specific antibody levels and protection from parasitemia in a longitudinal treatment - reinfection cohort in Western Kenya. Antibodies to three epitopes were associated with 16-17% decreased parasitemia over an 18- week high transmission season. We are currently designing immunogens to enhance antibody responses to these three epitopes.
28468980	29	44	B-cell epitopes	T129	C0282581
28468980	62	77	malaria vaccine	T121,T129	C0206255
28468980	88	127	P. falciparum Schizont Egress Antigen-1	T116,T129	C3849939
28468980	128	137	Naturally	T169	C0205296
28468980	148	158	antibodies	T116,T129	C0003241
28468980	162	170	PfSEA-1A	T116,T129	C3849939
28468980	217	224	malaria	T047	C0024530
28468980	228	236	children	T100	C0008059
28468980	238	249	Vaccination	T061	C0042196
28468980	253	257	mice	T015	C0025929
28468980	263	271	PbSEA-1A	T129	C4040232
28468980	282	293	parasitemia	T047	C0242723
28468980	326	349	Plasmodium berghei ANKA	T204	C0032149
28468980	376	390	immunogenicity	T038	C4277607
28468980	394	402	PfSEA-1A	T116,T129	C3849939
28468980	431	446	B-cell epitopes	T129	C0282581
28468980	453	460	peptide	T116	C0030956
28468980	461	472	microarrays	T075	C1136348
28468980	485	494	anti-sera	T116,T121,T129	C0020960
28468980	500	509	rPfSEA-1A	T116,T129	C3849939
28468980	512	522	vaccinated	T033	C1519885
28468980	533	541	primates	T015	C0033147
28468980	546	555	evaluated	T058	C0220825
28468980	581	588	epitope	T129	C0003316
28468980	599	607	antibody	T116,T129	C0003241
28468980	635	646	parasitemia	T047	C0242723
28468980	665	674	treatment	T061	C0087111
28468980	677	688	reinfection	T169	C0205339
28468980	689	695	cohort	T098	C0599755
28468980	699	712	Western Kenya	T083	C0022558
28468980	714	724	Antibodies	T116,T129	C0003241
28468980	734	742	epitopes	T129	C0003316
28468980	781	792	parasitemia	T047	C0242723
28468980	805	809	week	T079	C0439230
28468980	815	827	transmission	T070	C1521797
28468980	863	873	immunogens	T116,T121,T129	C0042213
28468980	885	903	antibody responses	T038	C0003261
28468980	919	927	epitopes	T129	C0003316